Systemic Therapy for HCC: A Rapidly Evolving Landscape

A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.

The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.

A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.